  |
Lægemiddelstofklassifikation ATC |
M | ||
  |
Antineoplastiske og immunomodulerende midler |
ML | ||
   |
immunsuppressiva |
ML04 | ||
 |
immunsuppressiva |
ML04A | ||
|
monoklonale antistoffer |
ML04AG | ||
 |
muromonab-CD3 |
ML04AG01 | ||
 |
efalizumab |
ML04AG02 | ||
 |
natalizumab |
ML04AG03 | ||
 |
belimumab |
ML04AG04 | ||
 |
vedolizumab |
ML04AG05 | ||
 |
alemtuzumab |
ML04AG06 | ||
 |
begelomab |
ML04AG07 | ||
 |
ocrelizumab |
ML04AG08 | ||
 |
emapalumab |
ML04AG09 | ||
 |
inebilizumab |
ML04AG10 | ||
 |
anifrolumab |
ML04AG11 | ||
 |
ofatumumab |
ML04AG12 | ||
 |
teprotumumab |
ML04AG13 | ||
 |
ublituximab |
ML04AG14 | ||
 |
divozilimab |
ML04AG15 | ||
 |
rozanolixizumab |
ML04AG16 | ||
 |
seniprutug |
ML04AG17 |
TEXT